Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Porter

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Microbiology (Reading, England)|October 30, 2008
The transcription programme of the protein-primed halovirus SH1Kate Porter, Brendan E Russ, Ji Yang, et al.
Archaea (Vancouver, B.C.)|April 16, 2013
PH1: an archaeovirus of Haloarcula hispanica related to SH1 and HHIV-2Kate Porter, Sen-Lin Tang, Chung-Pin Chen, et al.
Virology|April 13, 2005
SH1: A novel, spherical halovirus isolated from an Australian hypersaline lakeKate Porter, Petra Kukkaro, Jaana K H Bamford, et al.
Bioorganic & Medicinal Chemistry Letters|January 17, 2015
Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitroEdward M Tyndall, Alistair G Draffan, Barbara Frey, et al.
Contemporary Clinical Trials|December 1, 2025
Assessment of a novel functional food modulating the microbiota-inflammation-brain axis in patients with heart failure and/or /atrial fibrillation patients (the AMBROSIA study): Protocol for a randomized controlled trialSimone Baldi, Francesca Cuffaro, Edda Russo, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2014
Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agentsAlistair G Draffan, Barbara Frey, Benjamin H Fraser, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV AgentsAlistair G Draffan, Barbara Frey, Brett Pool, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Microbiology (Reading, England)|October 30, 2008
The transcription programme of the protein-primed halovirus SH1Kate Porter, Brendan E Russ, Ji Yang, et al.
Archaea (Vancouver, B.C.)|April 16, 2013
PH1: an archaeovirus of Haloarcula hispanica related to SH1 and HHIV-2Kate Porter, Sen-Lin Tang, Chung-Pin Chen, et al.
Virology|April 13, 2005
SH1: A novel, spherical halovirus isolated from an Australian hypersaline lakeKate Porter, Petra Kukkaro, Jaana K H Bamford, et al.
Bioorganic & Medicinal Chemistry Letters|January 17, 2015
Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitroEdward M Tyndall, Alistair G Draffan, Barbara Frey, et al.
Contemporary Clinical Trials|December 1, 2025
Assessment of a novel functional food modulating the microbiota-inflammation-brain axis in patients with heart failure and/or /atrial fibrillation patients (the AMBROSIA study): Protocol for a randomized controlled trialSimone Baldi, Francesca Cuffaro, Edda Russo, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2014
Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agentsAlistair G Draffan, Barbara Frey, Benjamin H Fraser, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV AgentsAlistair G Draffan, Barbara Frey, Brett Pool, et al.
Pageof 2